Brill, E., Yokoyama, T., Nair, J., Yu, M., Ahn, Y., & Lee, J. (2017). Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer. Oncotarget, 8(67), 111026-111040. https://doi.org/10.18632/oncotarget.22195 (Original work published 2017)